References
- Ryng S, Machoń Z, Głowiak T. Synthesis and X-ray structure of new 5-amino-methyl-4-isoxazolecarboxylic acid azides. J Chem Crystal 1994;24:483–488
- Bartlett RR, Dimitrijevic M, Mattar T, et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991;32:10–21
- Mazzei M, Sottofattori E, Dondero R, et al. N,N-Dialkylaminosubstitued chromones and isoxazoles as potential anti-inflammatory agents. Il Farmaco 1999;54:452–460
- Ryng S, Zimecki M, Mączyński M, et al. Immunosuppressive activity of an isoxazolo[5,4-e]triazepine-compound RM-33. I. Effects on the humoral and cellular immune response in mice. Pharmacol Rep 2005;57:195–202
- Zimecki M, Ryng S, Mączyński M, et al. Immunosuppressive activity of an isoxazolo[5,4-e]triazepine-compound RM-33. II. Effects on the carrageenan-induced inflammation. Pharmacol Rep 2006;58:236–241
- Zimecki M, Arytm J, Ryng S, Obmińska-Mrukowicz B. RM-11, an isoxazole derivative, accelerates restoration of the immune function in mice treated with cyclophosphamide. Pharmacol Rep 2008;60:183–189
- Zimecki M, Arytm J, Kocięba M, et al. Restoration of immune system function is accelerated in immunocompromised mice by the B-cell-tropic isoxazole R-11. Pharmacol Rep 2012;64:403–411
- Mączyński M, Zimecki M, Ryng S. A new class of isoxazole derivatives: the M 1-9 series of compounds with immunotropic activity. Acta Pol Pharm Drug Res 2008;65:241–244
- Mączyński M, Zimecki M, Taraszkiewicz M, Ryng S. Synthesis, immunological activity and computational study of 5-amino-3-methyl-4-isoxazolecarboxylic acid semicarbazides and thiosemicarbazides. Acta Pol Pharm Drug Res 2008;65:543–549
- Ryng S, Głowiak T. Nucleophilic substitution of an acyl azide: general method for the preparation of 5-amino-3-methyl-4-isoxazolecarboxylic acid amides and hydrazides. Synthetic Commun 1997;27:1359–1368
- Regiec A, Płoszaj P. New method of obtaining of 5-amino-3-methyl-4-isoxazolecarbohydrazide. Patent application number P.399717; 2012
- McCluskey C, Quinn JP, McGrath JW. An evaluation of three new-generation tetrazolium salts for the measurement of respiratory activity in activated sludge microorganisms. Microb Ecol 2005;49:379–387
- Alley MC, Scudiero DA, Monks A. Feasibility of drug with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589–601
- Stoker MGP. Role of diffusion boundary layer in contact inhibition of growth. Nature 1973;246:200–203
- Fracasso PM, Sartorelli AC. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic aerobic EMT6 and Chinese hamster ovary cells. Cancer Res 1986;46:3939–3944
- Raetz CR. Bacterial endotoxins: extraordinary lipids that activate eukaryotic signal transduction. J Bacteriol 1993;175:5745–5753
- Geetha S, Sai Ram M, Singh V, et al. C. Anti-oxidant and immunomodulatory properties of seabuckthorn (Hippophae rhamnoides) – an in vitro study. J Ethnopharmacol 2002;79:373–378
- Tosi MF. Innate immune responses to infection. J Allergy Clin Immunol 2005;116:241–249
- Beutler B. Innate immunity: an overview. Mol Immunol 2004;40:845–859
- Fiers W. Tumor necrosis factor: characterization at the molecular, cellular and in vivo level. FEBS Lett 1991;285:199–212
- Baseta JG, Stutman O. TNF regulates thymocyte production by apoptosis and proliferation of the triple negative (CD3-CD4-CD8-) subset. J Immunol 2000;165:5621–5630
- Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood J 1991;77:1627–1652
- Dinarello CA, Cannon JG, Mier JW, et al. Multiple biological activities of human recombinant interleukin-1. J Clin Invest 1986;77:1734–1739